Last €98.17 EUR
Change Today +1.70 / 1.76%
Volume 78.0
J7Z On Other Exchanges
Symbol
Exchange
Berlin
As of 1:50 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

jazz pharmaceuticals plc (J7Z) Snapshot

Open
€95.33
Previous Close
€96.47
Day High
€100.56
Day Low
€95.33
52 Week High
02/24/14 - €128.53
52 Week Low
05/8/13 - €40.85
Market Cap
5.8B
Average Volume 10 Days
26.6
EPS TTM
--
Shares Outstanding
59.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for JAZZ PHARMACEUTICALS PLC (J7Z)

jazz pharmaceuticals plc (J7Z) Related Businessweek News

No Related Businessweek News Found

jazz pharmaceuticals plc (J7Z) Details

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients. In addition, it offers products in the areas of hematology and oncology drugs, such as Asparec, which is in Phase I clinical trial for the treatment of patients with ALL with E.coli asparaginase hypersensitivity; Defibrotide for the treatment of severe VOD; and Leukotac, an anti-CD25 monoclonal antibody that is in Phase III clinical trials and is intended for the treatment of steroid-refractory acute GvHD. The company is headquartered in Dublin, Ireland.

810 Employees
Last Reported Date: 02/25/14

jazz pharmaceuticals plc (J7Z) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: $722.2K
Executive Vice President and General Counsel
Total Annual Compensation: $607.8K
Chief Medical Officer, Executive Vice Preside...
Total Annual Compensation: $547.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $379.3K
Consultant
Total Annual Compensation: $446.8K
Compensation as of Fiscal Year 2012.

jazz pharmaceuticals plc (J7Z) Key Developments

Jazz Pharmaceuticals plc and Gentium S.p.A Launch Veno-Occlusive Disease Drug

Jazz Pharmaceuticals plc and Gentium S.p.A. have launched Defitelio, the first licensed product for the treatment of severe hepatic veno-occlusive disease, or severe VOD or sVOD, in patients over one month of age undergoing haematopoietic stem cell transplantation, or HSCT therapy. The efficacy of Defitelio to treat sVOD in HSCT patients is supported by data from a pivotal, multi-centre Phase III trial that evaluated Defitelio for the treatment of sVOD compared with a historical control group of patients who had received standard supportive care. In this trial, Defitelio was shown to provide a significant increase in survival rates for patients with sVOD in HSCT. The results demonstrated a 52% increase in survival at 100 days after transplantation for patients treated with Defitelio compared to patients in the historical control group (38.2% in the Defitelio group vs. 25.0% in the historical control group; p=0.0341). In the clinical trial, 23.5% of patients treated with Defitelio achieved complete response at 100 days after transplantation versus 9.4% of patients in the historical control group (p=0.013). The efficacy data from this pivotal trial are supported with data from a Phase II dose-finding study, as well as data from the International Compassionate Use Programme and an interim analysis (subset of patients with sVOD) of an ongoing, open-label treatment investigational new drug (IND) study being conducted in the US. Additionally, data derived from an independent registry in the US supported the European approval of Defitelio for use in patients with sVOD. Treatment with Defitelio has generally been well tolerated in all age groups. In the Phase III pivotal trial, the overall incidence of adverse events was similar in the Defitelio treatment group and in the control group. The most frequent adverse events observed during pre-marketing use were haemorrhage, hypotension and coagulopathy.

Jazz Pharmaceuticals Public Limited Company Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-12-2014 08:30 AM

Jazz Pharmaceuticals Public Limited Company Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-12-2014 08:30 AM. Venue: Loews Miami Beach Hotel, Miami, Florida, United States. Speakers: Bruce C. Cozadd, Co-Founder, Executive Chairman and Chief Executive Officer.

Jazz Pharmaceuticals plc Announces Unaudited Consolidated Financial Results for the Full Year and the Fourth Quarter Ended December 31, 2013; Provides Earnings Guidance for the Year 2014

Jazz Pharmaceuticals plc announced unaudited consolidated financial results for the full year and the fourth quarter ended December 31, 2013. Adjusted net income for 2013 was $388.3 million, or $6.31 per diluted share, compared to $290.4 million, or $4.82 per diluted share, for 2012. GAAP net income for 2013 was $216.3 million, or $3.51 per diluted share, compared to $288.6 million, or $4.79 per diluted share, for 2012. GAAP income from continuing operations for 2013 was $216.3 million, or $3.51 per diluted share, compared to $261.1 million, or $4.34 per diluted share, for 2012. Total revenues for the year ended December 31, 2013 were $872.4 million, an increase of 49% over total revenues of $586.0 million for the year ended December 31, 2012. Income from operations was $340.312 million against $197.844 million a year ago. Income from continuing operations before income tax provision was $307.950 million against $177.355 million a year ago. Adjusted net income for the fourth quarter of 2013 was $106.1 million, or $1.72 per diluted share, compared to $93.9 million, or $1.53 per diluted share, for the fourth quarter of 2012. GAAP net income for the fourth quarter of 2013 was $55.3 million, or $0.90 per diluted share, compared to $200.6 million, or $3.28 per diluted share, for the fourth quarter of 2012. During the fourth quarter of 2012, the company reversed the valuation allowance against substantially all of its U.S. deferred tax assets, which increased GAAP net income per diluted share by $1.73 and $1.70 for the full year and the fourth quarter of 2012, respectively. GAAP income from continuing operations for the fourth quarter of 2013 was $55.3 million, or $0.90 per diluted share, compared to $166.2 million, or $2.71 per diluted share, for the fourth quarter of 2012. Total revenues for the fourth quarter of 2013 were $235.8 million, an increase of 28% over total revenues of $183.7 million for the fourth quarter of 2012. This increase was driven primarily by increased net sales of Xyrem(R) (sodium oxybate) oral solution and Erwinaze(R)/Erwinase(R) (asparaginase Erwinia chrysanthemi). Income from operations was $94.499 million against $67.378 million a year ago. Income from continuing operations before income tax provision was $87.357 million against $57.446 million a year ago. For the year 2014, the company expects revenue between $1,100 million and $1,160 million; total net product sales between $1,093 million and $1,153 million; adjusted gross margin between 91% and 92%; GAAP net income per diluted share attributable to the company between $2.31 and $2.84; Non-GAAP adjusted net income per diluted share attributable to the company between $8.00 and $8.25; Non-GAAP adjusted net income attributable to the company between $496 million and $520 million. GAAP effective tax rate is expected to be higher in 2014 compared to last year, largely due to the impact of the upfront payment to Aerial BioPharma for JZP-110, which has no associated tax benefit. Adjusted non-GAAP effective tax rate is expected to remain in the high-teens in 2014, similar to 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
J7Z:GR €98.17 EUR +1.70

J7Z Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $22.81 USD +0.10
Alkermes PLC $44.12 USD -0.91
BioMarin Pharmaceutical Inc $60.89 USD -0.48
Impax Laboratories Inc $23.92 USD -0.39
Salix Pharmaceuticals Ltd $101.06 USD +0.40
View Industry Companies
 

Industry Analysis

J7Z

Industry Average

Valuation J7Z Industry Range
Price/Earnings 38.7x
Price/Sales 9.0x
Price/Book 6.1x
Price/Cash Flow 26.8x
TEV/Sales 7.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit www.jazzpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.